Biotechnology

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.

As BioPharma races to adopt AI, fragmented data remains a huge hurdle. A Boston forum aims to find solutions for building a trusted digital foundation.

For the 8th straight year, Equashield dominates the CSTD market. We explore the tech, trust, and automation driving its success in protecting workers.

With two pivotal trial readouts looming and cash projected to last only into Q4, Tvardi Therapeutics faces a make-or-break year for its STAT3 inhibitors.

At a top Paris expo, GUYU's biotech arm BioQ unveiled cellular anti-aging ingredients, signaling a new era of Chinese innovation in the beauty supply chain.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

A three-month FDA delay for a new LEQEMBI injection highlights the high-stakes race for a convenient Alzheimer's therapy and its complex safety hurdles.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

The biotech supplier swung to profitability and positive cash flow, driven by a major cost overhaul and strong demand in its core nucleic acid business.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.

A new health campaign uses emotional appeals to boost adult vaccination in Southeast Asia, highlighting the complex role of pharma in public health.

With its new CCO, the AI health-tech firm aims to commercialize its patient-data platform, tackling billion-dollar delays in drug development.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.

Sesen launches a new platform blending AI and human experts to streamline complex medical translation, aiming for faster, safer global market access.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A massive $250M investment could replace a 40-pill daily burden with a single tablet for patients with pancreatic insufficiency, disrupting a market in crisis.

A leading scientific body is ditching 'longevity' for 'geroscience,' aiming to bring scientific rigor to a field rife with hype and misinformation.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

Quebec biotech firm Aplantex secures $5M to scale its unique green technology, moving from research to industrial production of sustainable ingredients.

With a massive new war chest, the secretive Multi Investment plans to pour capital into fintech, deep tech, and biotech, shaking up innovation funding.